Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 279 participants.

Also called NCT06987695

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 279 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06987695
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06987695. Randomized; double masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2027-04-27 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
Acronym
MARITIME-3-J
Condition
Obesity Disease
Intervention (Drug)
Maridebart cafraglutide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct06987695
Content hash
d084faad060f4aeb08457122f169f4d080f7cb506a54a13397e456640a3d3091